FORESIGHT: FEASIBILITY OF OLANZAPINE AT REDUCED DOSE IN HIGHLY EMETOGENIC CHEMOTHERAPY: A RANDOMISED CONTROLLED TRIAL AGAINST APREPITANT IN TRIPLE THERAPY

Registry ID

2019-389

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

HOPITAL CHARLES LEMOYNE

Start date

2019-04-29

Last update

2019-04-15

Conditions

• NAUSEA

Related clinical trials

• PROSPECTIVEEVALUATION OF SYMPTOMS AND OPEN LABEL HALOPERIDOL IN CANNABINOID HYPEREMESIS SYNDROME (HALO).

View on source registry